

# Per Morten Sandset

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/266259/per-morten-sandset-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

310  
papers

9,888  
citations

49  
h-index

88  
g-index

328  
ext. papers

11,225  
ext. citations

7.3  
avg, IF

5.94  
L-index

#	Paper	IF	Citations
310	Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. <i>Lancet, The</i> , <b>2012</b> , 379, 31-8	40	613
309	Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. <i>European Heart Journal</i> , <b>2006</b> , 27, 1038-47	9.5	608
308	Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). <i>Thrombosis Research</i> , <b>1988</b> , 50, 803-13	8.2	360
307	Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. <i>Lancet, The</i> , <b>2000</b> , 355, 1205-10	40	339
306	Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2008</b> , 6, 905-12	15.4	262
305	Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 1308-13	15.4	253
304	Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium--a register-based case-control study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2008</b> , 198, 233.e1-7	6.4	244
303	Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. <i>Lancet Haematology, the</i> , <b>2016</b> , 3, e64-71	14.6	216
302	Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. <i>Journal of Thrombosis and Haemostasis</i> , <b>2009</b> , 7, 1268-75	15.4	211
301	Detection of arterial emboli using Doppler ultrasound in rabbits. <i>Stroke</i> , <b>1991</b> , 22, 253-8	6.7	206
300	Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. <i>Blood</i> , <b>2003</b> , 101, 4387-92	2.2	195
299	Association between acute hypobaric hypoxia and activation of coagulation in human beings. <i>Lancet, The</i> , <b>2000</b> , 356, 1657-8	40	190
298	The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. <i>Thrombosis Research</i> , <b>1989</b> , 55, 459-70	8.2	156
297	Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1991</b> , 88, 708-12	11.5	154
296	A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. <i>Thrombosis Research</i> , <b>1987</b> , 47, 389-400	8.2	104
295	The Effects of Hormone Replacement Therapy (HRT) on Hemostatic Variables in Women with Previous Venous Thromboembolism [Results from a Randomized, Double-Blind, Clinical Trial. <i>Thrombosis and Haemostasis</i> , <b>2001</b> , 85, 775-781	7	96
294	Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). <i>Journal of Headache and Pain</i> , <b>2017</b> , 18, 108	8.8	91

293	Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1997</b> , 17, 2548-53	9.4	88
292	Catheter-directed Venous Thrombolysis in acute iliofemoral vein thrombosis—the CaVenT study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771). <i>American Heart Journal</i> , <b>2007</b> , 154, 808-14	4.9	86
291	Targeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials. <i>Lancet Neurology</i> , <b>2013</b> , 12, 539-45	24.1	85
290	Management of pregnant women with mechanical heart valve prosthesis: thromboprophylaxis with low molecular weight heparin. <i>Thrombosis Research</i> , <b>2009</b> , 124, 262-7	8.2	85
289	Fibrinogen and fibrin induce synthesis of proinflammatory cytokines from isolated peripheral blood mononuclear cells. <i>Thrombosis and Haemostasis</i> , <b>2007</b> , 97, 822-9	7	85
288	Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , <b>1994</b> , 14, 223-9		85
287	D-dimer level is associated with the extent of pulmonary embolism. <i>Thrombosis Research</i> , <b>2007</b> , 120, 281-8	8.2	81
286	Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2000</b> , 20, 259-65	9.4	77
285	Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , <b>1991</b> , 11, 138-45		76
284	The present status of tissue factor pathway inhibitor. <i>Blood Coagulation and Fibrinolysis</i> , <b>1992</b> , 3, 439-449		75
283	Chromogenic substrate assay of extrinsic pathway inhibitor (EPI). <i>Blood Coagulation and Fibrinolysis</i> , <b>1991</b> , 2, 425-434	1	74
282	Determinants of the APTT- and ETP-based APC sensitivity tests. <i>Journal of Thrombosis and Haemostasis</i> , <b>2005</b> , 3, 1488-94	15.4	72
281	Management of suspected pulmonary embolism (PE) by D-dimer and multi-slice computed tomography in outpatients: an outcome study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2005</b> , 3, 1926-32	15.4	72
280	Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. <i>British Journal of Haematology</i> , <b>2001</b> , 115, 415-20	4.5	70
279	Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2958-2967	15.4	69
278	Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. <i>European Journal of Vascular and Endovascular Surgery</i> , <b>2021</b> , 61, 9-82	2.3	69
277	Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. <i>Leukemia</i> , <b>2009</b> , 23, 162-9	10.7	64
276	Determinants of early and long-term efficacy of catheter-directed thrombolysis in proximal deep vein thrombosis. <i>Journal of Vascular and Interventional Radiology</i> , <b>2013</b> , 24, 17-24; quiz 26	2.4	63

275	Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. <i>Blood Coagulation and Fibrinolysis</i> , <b>1991</b> , 2, 713-21	1	62
274	Prevalence and predictors for post-thrombotic syndrome 3 to 16 years after pregnancy-related venous thrombosis: a population-based, cross-sectional, case-control study. <i>Journal of Thrombosis and Haemostasis</i> , <b>2012</b> , 10, 840-7	15.4	59
273	Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT study. <i>BMJ Open</i> , <b>2013</b> , 3, e002984	3	56
272	Procedure-specific Risks of Thrombosis and Bleeding in Urological Cancer Surgery: Systematic Review and Meta-analysis. <i>European Urology</i> , <b>2018</b> , 73, 242-251	10.2	55
271	Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - a European Perspective. <i>Thrombosis Research</i> , <b>2012</b> , 129, 426-33	8.2	55
270	Severe syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP) in the 18th week of pregnancy associated with the antiphospholipid-antibody syndrome. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , <b>2003</b> , 82, 679-80	3.8	54
269	Factor VII and extrinsic pathway inhibitor in acute coronary disease. <i>British Journal of Haematology</i> , <b>1989</b> , 72, 391-6	4.5	54
268	Deep vein thrombosis: a 7-year follow-up study. <i>Journal of Internal Medicine</i> , <b>1993</b> , 234, 71-5	10.8	53
267	Multidetector computed tomography (MDCT) in the diagnosis of pulmonary embolism: interobserver agreement among radiologists with varied levels of experience. <i>Acta Radiologica</i> , <b>2007</b> , 48, 165-70	2	51
266	Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). <i>Thrombosis and Haemostasis</i> , <b>2000</b> , 84, 961-7	7	51
265	Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2015</b> , 70, 329-37	3.1	50
264	An exploratory trial of cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated immune activation and improved T cell-dependent vaccine responses. <i>Journal of Virology</i> , <b>2011</b> , 85, 6557-66	6.6	50
263	Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. <i>British Journal of Haematology</i> , <b>1998</b> , 101, 638-46	4.5	50
262	The association between the proximal extension of the clot and the severity of pulmonary embolism (PE): a proposal for a new radiological score for PE. <i>Journal of Internal Medicine</i> , <b>2007</b> , 261, 74-81	10.8	49
261	Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2003</b> , 110, 139-144	3.7	49
260	Deep vein thrombosis after elective cesarean section. <i>Thrombosis Research</i> , <b>2004</b> , 113, 283-8	8.2	49
259	The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. <i>Maturitas</i> , <b>2005</b> , 52, 111-8	5	48
258	Depletion of Intravascular Pools of Tissue Factor Pathway Inhibitor (TFPI) during Repeated or Continuous Intravenous Infusion of Heparin in Man. <i>Thrombosis and Haemostasis</i> , <b>1996</b> , 76, 703-709	7	46

257	Hemostatic activation in acute ischemic stroke. <i>Thrombosis Research</i> , <b>2001</b> , 101, 13-21	8.2	44
256	Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy. <i>Thrombosis Research</i> , <b>1998</b> , 91, 177-81	8.2	42
255	Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor. <i>Thrombosis and Haemostasis</i> , <b>2008</b> , 99, 1040-8	7	42
254	Mechanisms of thrombosis related to hormone therapy. <i>Thrombosis Research</i> , <b>2009</b> , 123 Suppl 2, S70-3	8.2	41
253	Health-related quality of life after pulmonary embolism: a cross-sectional study. <i>BMJ Open</i> , <b>2016</b> , 6, e013086		41
252	The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study. <i>Thrombosis Research</i> , <b>2000</b> , 98, 19-27	8.2	40
251	Women's experiences in relation to stillbirth and risk factors for long-term post-traumatic stress symptoms: a retrospective study. <i>BMJ Open</i> , <b>2013</b> , 3, e003323	3	38
250	Systematic reviews of observational studies of risk of thrombosis and bleeding in urological surgery (ROTBUS): introduction and methodology. <i>Systematic Reviews</i> , <b>2014</b> , 3, 150	3	37
249	Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1995</b> , 15, 879-85	9.4	37
248	Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants. <i>British Journal of Haematology</i> , <b>2007</b> , 136, 131-7	4.5	36
247	INR calibration of Owren-type prothrombin time based on the relationship between PT% and INR utilizing normal plasma samples. <i>Thrombosis and Haemostasis</i> , <b>2004</b> , 91, 1223-31	7	36
246	Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2013</b> , 11, 1032-42	15.4	35
245	The association of antiphospholipid antibodies with pregnancy-related first time venous thrombosis--a population-based case-control study. <i>Thrombosis Research</i> , <b>2010</b> , 125, e222-7	8.2	35
244	Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins. <i>British Journal of Haematology</i> , <b>1999</b> , 107, 756-62	4.5	35
243	Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility. <i>BMC Cancer</i> , <b>2011</b> , 11, 357	4.8	34
242	Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. <i>Journal of Thrombosis and Haemostasis</i> , <b>2007</b> , 5, 2204-10	15.4	34
241	Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). <i>Journal of Headache and Pain</i> , <b>2018</b> , 19, 76	8.8	34
240	Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis. <i>Intensive Care Medicine</i> , <b>2015</b> , 41, 1209-19	14.5	33

239	The factor V Leiden, prothrombin gene 20210GA, methylenetetrahydrofolate reductase 677CT and platelet glycoprotein IIIa 1565TC mutations in patients with acute ischemic stroke and atrial fibrillation. <i>Stroke</i> , <b>2007</b> , 38, 1069-71	6.7	33
238	A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI). <i>Journal of Thrombosis and Haemostasis</i> , <b>2005</b> , 3, 651-8	15.4	33
237	Tissue Factor Pathway Inhibitor: Clinical Deficiency States. <i>Thrombosis and Haemostasis</i> , <b>1997</b> , 78, 467-470		32
236	An enzyme linked immunosorption assay for tissue factor pathway inhibitor. <i>Thrombosis Research</i> , <b>1997</b> , 87, 447-59	8.2	31
235	The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. <i>Journal of Thrombosis and Haemostasis</i> , <b>2008</b> , 6, 393-395	15.4	31
234	Impaired circadian variations of haemostatic and fibrinolytic parameters in tetraplegia. <i>British Journal of Haematology</i> , <b>2002</b> , 119, 1011-6	4.5	31
233	Procedure-specific Risks of Thrombosis and Bleeding in Urological Non-cancer Surgery: Systematic Review and Meta-analysis. <i>European Urology</i> , <b>2018</b> , 73, 236-241	10.2	30
232	Extrinsic Pathway Inhibitor in Elective Surgery: A Comparison with other Coagulation Inhibitors. <i>Thrombosis and Haemostasis</i> , <b>1989</b> , 62, 856-860	7	30
231	Classification of stillbirths and risk factors by cause of death--a case-control study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , <b>2013</b> , 92, 325-33	3.8	29
230	Venous thromboembolism associated with pregnancy and hormonal therapy. <i>Best Practice and Research in Clinical Haematology</i> , <b>2012</b> , 25, 319-32	4.2	29
229	Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 2443-9	15.4	29
228	A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1. <i>Thrombosis Research</i> , <b>2000</b> , 97, 463-72	8.2	29
227	Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans. <i>Thrombosis Research</i> , <b>1996</b> , 84, 267-78	8.2	29
226	Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. <i>Thrombosis Research</i> , <b>2007</b> , 120, 371-9	8.2	28
225	Defective thrombus formation in mice lacking endogenous factor VII activating protease (FSAP). <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 113, 870-80	7	27
224	Long-term quality of life after pregnancy-related deep vein thrombosis and the influence of socioeconomic factors and comorbidity. <i>Journal of Thrombosis and Haemostasis</i> , <b>2011</b> , 9, 1931-6	15.4	27
223	Increased acquired activated protein C resistance in unselected patients with hematological malignancies. <i>Journal of Thrombosis and Haemostasis</i> , <b>2008</b> , 6, 1482-7	15.4	27
222	Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. <i>Maturitas</i> , <b>2006</b> , 55, 278-87	5	27

221	The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor. <i>Thrombosis Journal</i> , <b>2017</b> , 15, 6	5.6	26
220	Coagulation inhibitor levels in pneumonia and stroke: changes due to consumption and acute phase reaction. <i>Journal of Internal Medicine</i> , <b>1989</b> , 225, 311-6	10.8	26
219	Anxiety, depression and relationship satisfaction in the pregnancy following stillbirth and after the birth of a live-born baby: a prospective study. <i>BMC Pregnancy and Childbirth</i> , <b>2018</b> , 18, 41	3.2	25
218	Mechanisms of hormonal therapy related thrombosis. <i>Thrombosis Research</i> , <b>2013</b> , 131 Suppl 1, S4-7	8.2	25
217	Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke. <i>Stroke</i> , <b>2015</b> , 46, 877-9	6.7	25
216	Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study. <i>BMC Cancer</i> , <b>2014</b> , 14, 845	4.8	25
215	Are there patients with acute ischemic stroke and atrial fibrillation that benefit from low molecular weight heparin?. <i>Stroke</i> , <b>2006</b> , 37, 452-5	6.7	25
214	Extrinsic coagulation pathway inhibitor and heparin cofactor II during normal and hypertensive pregnancy. <i>Thrombosis Research</i> , <b>1989</b> , 55, 665-70	8.2	24
213	Development and validation of a tool for patient reporting of symptoms and signs of the post-thrombotic syndrome. <i>Thrombosis and Haemostasis</i> , <b>2016</b> , 115, 361-367	7	24
212	Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome. <i>Thrombosis Research</i> , <b>2018</b> , 163, 6-11	8.2	23
211	TFPI and TFPI are expressed at the surface of breast cancer cells and inhibit TF-FVIIa activity. <i>Journal of Hematology and Oncology</i> , <b>2013</b> , 6, 5	22.4	23
210	Visualization of deep veins and detection of deep vein thrombosis (DVT) with balanced turbo field echo (b-TFE) and contrast-enhanced T1 fast field echo (CE-FFE) using a blood pool agent (BPA). <i>Journal of Magnetic Resonance Imaging</i> , <b>2010</b> , 31, 416-24	5.6	23
209	The performance of STA-Liatest D-dimer assay in out-patients with suspected pulmonary embolism. <i>British Journal of Haematology</i> , <b>2006</b> , 132, 210-5	4.5	23
208	Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI. <i>Thrombosis Research</i> , <b>1991</b> , 62, 607-14	8.2	23
207	High plasma levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced cancer. <i>Acta Chirurgica Scandinavica</i> , <b>1989</b> , 155, 389-93		23
206	Health-related quality of life after deep vein thrombosis. <i>SpringerPlus</i> , <b>2016</b> , 5, 1278		23
205	Residual rates of reflux and obstruction and their correlation to post-thrombotic syndrome in a randomized study on catheter-directed thrombolysis for deep vein thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , <b>2014</b> , 2, 123-30	3.2	22
204	Tissue factor pathway inhibitor (TFPI)--an update. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>1996</b> , 26 Suppl 4, 154-65		22

203	Long-term impact of pregnancy-related venous thrombosis on quality-of-life, general health and functioning: results of a cross-sectional, case-control study. <i>BMJ Open</i> , <b>2012</b> , 2,	3	21
202	Activated protein C resistance and graft occlusion after coronary artery bypass surgery. <i>Thrombosis Research</i> , <b>1995</b> , 79, 223-6	8.2	21
201	Coagulation inhibition and activation in pancreatic cancer. Changes during progress of disease. <i>Cancer</i> , <b>1992</b> , 70, 2067-72	6.4	21
200	EPAS1/HIF-2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro-thrombotic potential in endothelial cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2016</b> , 1862, 670-678	6.9	20
199	Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers. <i>Journal of Thrombosis and Haemostasis</i> , <b>2008</b> , 6, 928-34	15.4	20
198	Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1. <i>BMC Cardiovascular Disorders</i> , <b>2006</b> , 6, 40	2.3	20
197	Discrepancy between fibrinogen concentrations determined by clotting rate and clottability assays during the acute-phase reaction. <i>Thrombosis Research</i> , <b>2000</b> , 100, 397-403	8.2	20
196	Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 1874-1882	15.4	20
195	The role of microRNA-27a/b and microRNA-494 in estrogen-mediated downregulation of tissue factor pathway inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 1226-37	15.4	20
194	Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. <i>British Journal of Haematology</i> , <b>2012</b> , 158, 811-4	4.5	19
193	The association of antiphospholipid antibodies with intrauterine fetal death: a case-control study. <i>Thrombosis Research</i> , <b>2012</b> , 130, 32-7	8.2	19
192	The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 109, 606-13	7	19
191	Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2011</b> , 37, 328-36	5.3	19
190	Overexpression of both TFPI and TFPI induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells. <i>Molecular Carcinogenesis</i> , <b>2010</b> , 49, 951-63	5	19
189	Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2008</b> , 115, 773-9	3.7	19
188	Cerebral microembolus detection in an unselected acute ischemic stroke population. <i>Cerebrovascular Diseases</i> , <b>2000</b> , 10, 403-8	3.2	19
187	Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins. <i>Blood Coagulation and Fibrinolysis</i> , <b>2000</b> , 11, 343-8	1	19
186	Low molecular weight heparin prevents activation of coagulation in a hypobaric environment. <i>Blood Coagulation and Fibrinolysis</i> , <b>2001</b> , 12, 371-4	1	19



185	Diagnostic scales for the post-thrombotic syndrome. <i>Thrombosis Research</i> , <b>2018</b> , 164, 110-115	8.2	18
184	Functional characterization of polymorphisms in the human TFPI gene. <i>Biochemical and Biophysical Research Communications</i> , <b>2010</b> , 397, 106-11	3.4	18
183	Rebound activation of coagulation after treatment with unfractionated heparin and not with low molecular weight heparin is associated with partial depletion of tissue factor pathway inhibitor and antithrombin. <i>Thrombosis Research</i> , <b>2000</b> , 100, 413-7	8.2	18
182	Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals. <i>British Journal of Haematology</i> , <b>1999</b> , 105, 641-7	4.5	18
181	Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix. <i>Blood Coagulation and Fibrinolysis</i> , <b>1994</b> , 5, 755-60	1	18
180	Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency. <i>Blood</i> , <b>2018</b> , 131, 1301-1310	2.2	17
179	Maternal familial hypercholesterolaemia (FH) confers altered haemostatic profile in offspring with and without FH. <i>Thrombosis Research</i> , <b>2013</b> , 131, 178-82	8.2	17
178	Assessing burden of illness following acute deep vein thrombosis: data quality, reliability and validity of the Norwegian version of VEINES-QOL/Sym, a disease-specific questionnaire. <i>Scandinavian Journal of Caring Sciences</i> , <b>2009</b> , 23, 369-74	2.3	17
177	Coagulation activation in young survivors of myocardial infarction (MI)--a population-based case-control study. <i>Thrombosis and Haemostasis</i> , <b>2004</b> , 92, 178-84	7	17
176	A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7. <i>Thrombosis Research</i> , <b>2017</b> , 157, 111-116	8.2	17
175	Enhanced thrombin generation and reduced intact protein S in processed solvent detergent plasma. <i>Thrombosis Research</i> , <b>2015</b> , 135, 167-74	8.2	16
174	Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells. <i>Blood Cells, Molecules, and Diseases</i> , <b>2013</b> , 51, 177-84	2.1	16
173	Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF. <i>Breast Cancer Research</i> , <b>2015</b> , 17, 44	8.3	16
172	Long-term impact of intrauterine fetal death on quality of life and depression: a case-control study. <i>BMC Pregnancy and Childbirth</i> , <b>2012</b> , 12, 43	3.2	16
171	Recurrent venous thrombosis, post-thrombotic syndrome and quality of life after catheter-directed thrombolysis in severe proximal deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2011</b> , 9, 1261-3	15.4	16
170	Validation of a new D-dimer microparticle enzyme immunoassay (AxSYM D-Dimer) in patients with suspected pulmonary embolism (PE). <i>Thrombosis Research</i> , <b>2007</b> , 120, 471-6	8.2	16
169	A daily glass of red wine induces a prolonged reduction in plasma viscosity: a randomized controlled trial. <i>Blood Coagulation and Fibrinolysis</i> , <b>2006</b> , 17, 471-6	1	16
168	Scoring Systems for Postthrombotic Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2017</b> , 43, 500-504	3	15

167	Adherence to mechanical thromboprophylaxis after surgery: A systematic review and meta-analysis. <i>Thrombosis Research</i> , <b>2015</b> , 136, 723-6	8.2	15
166	Women's values and preferences for thromboprophylaxis during pregnancy: a comparison of direct-choice and decision analysis using patient specific utilities. <i>Thrombosis Research</i> , <b>2015</b> , 136, 341-7	8.2	15
165	CXCL4-platelet factor 4, heparin-induced thrombocytopenia and cancer. <i>Thrombosis Research</i> , <b>2012</b> , 129 Suppl 1, S97-100	8.2	15
164	The ability of three global plasma assays to recognize thrombophilia. <i>Thrombosis Research</i> , <b>2004</b> , 113, 411-7	8.2	15
163	Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor?. <i>Thrombosis Research</i> , <b>1999</b> , 94, 213-20	8.2	15
162	Syndecan-3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells. <i>PLoS ONE</i> , <b>2015</b> , 10, e0117404	3.7	15
161	Compression Stockings for Preventing the Postthrombotic Syndrome in Patients with Deep Vein Thrombosis. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 447.e1-447.e20	2.4	15
160	Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer. <i>Journal of Thrombosis and Haemostasis</i> , <b>2016</b> , 14, 387-96	15.4	14
159	Women's values and preferences and health state valuations for thromboprophylaxis during pregnancy: A cross-sectional interview. <i>Thrombosis Research</i> , <b>2016</b> , 140, 22-9	8.2	14
158	Incidence and risk factors of fetal death in Norway: a case-control study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , <b>2011</b> , 90, 390-7	3.8	14
157	Heparin Treatment in 52 Patients with Progressive Ischemic Stroke. <i>Cerebrovascular Diseases</i> , <b>1994</b> , 4, 101-105	3.2	14
156	A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. <i>Seminars in Thrombosis and Hemostasis</i> , <b>1990</b> , 16 Suppl, 25-33	5.3	14
155	Oestrogen induced downregulation of TFPI expression is mediated by ER $\beta$ . <i>Thrombosis Research</i> , <b>2014</b> , 134, 138-43	8.2	13
154	Adaptation of trustworthy guidelines developed using the GRADE methodology: a novel five-step process. <i>Chest</i> , <b>2014</b> , 146, 727-734	5.3	13
153	Differential haemostatic risk factors for pregnancy-related deep-vein thrombosis and pulmonary embolism: a population-based case-control study. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 1165-71	7	13
152	Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy. <i>Stroke</i> , <b>2012</b> , 43, 952-7	6.7	13
151	Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state. <i>British Journal of Haematology</i> , <b>2006</b> , 132, 333-8	4.5	13
150	Serum lipids and regulation of tissue factor-induced coagulation in middle-aged men. <i>Thrombosis Research</i> , <b>2001</b> , 102, 3-13	8.2	13

149	Venous thromboembolism in the critically ill: A prospective observational study of occurrence, risk factors and outcome. <i>Acta Anaesthesiologica Scandinavica</i> , <b>2019</b> , 63, 630-638	1.9	13
148	The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial. <i>Thrombosis and Haemostasis</i> , <b>2001</b> , 85, 775-81	7	13
147	Quality of life after pulmonary embolism: first cross-cultural evaluation of the pulmonary embolism quality-of-life (PEmb-QoL) questionnaire in a Norwegian cohort. <i>Quality of Life Research</i> , <b>2015</b> , 24, 417-25	3.7	12
146	Altered hemostatic balance and endothelial activation in pregnant women with familial hypercholesterolemia. <i>Thrombosis Research</i> , <b>2007</b> , 120, 21-7	8.2	12
145	Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine. <i>Cardiology</i> , <b>2002</b> , 98, 6-12	1.6	12
144	Toxicity of gamma irradiated liposomes. 1. In vitro interactions with blood components. <i>International Journal of Pharmaceutics</i> , <b>1999</b> , 178, 33-46	6.5	12
143	Long-term anticoagulant therapy in cerebrovascular disease: does bleeding outweigh the benefit?. <i>Journal of Internal Medicine</i> , <b>1995</b> , 237, 323-9	10.8	12
142	The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. <i>Journal of Thrombosis and Haemostasis</i> , <b>2008</b> , 6, 393-5	15.4	12
141	Randomised controlled trial protocol to evaluate a fixed dose prothrombin complex concentrate against the variable dose in vitamin K antagonist related bleeding (PROPER3). <i>BMJ Open</i> , <b>2018</b> , 8, e020764	2.4	11
140	Melatonin stimulates release of tissue factor pathway inhibitor from the vascular endothelium. <i>Blood Coagulation and Fibrinolysis</i> , <b>2011</b> , 22, 254-9	1	11
139	Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism. <i>British Journal of Haematology</i> , <b>2011</b> , 154, 241-7	4.5	11
138	D-dimer levels and stroke progression in patients with acute ischemic stroke and atrial fibrillation. <i>Acta Neurologica Scandinavica</i> , <b>2011</b> , 124, 40-4	3.8	11
137	Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , <b>2009</b> , 50, 998-1004	1.9	11
136	Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy. <i>Blood Coagulation and Fibrinolysis</i> , <b>2010</b> , 21, 516-21	1	11
135	Physiological function of tissue factor pathway inhibitor and interaction with heparins. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>2000</b> , 30 Suppl 2, 48-56		11
134	TFPI alpha and beta regulate mRNAs and microRNAs involved in cancer biology and in the immune system in breast cancer cells. <i>PLoS ONE</i> , <b>2012</b> , 7, e47184	3.7	11
133	Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists. <i>Thrombosis Research</i> , <b>2020</b> , 185, 119-124	8.2	11
132	Antiphospholipid Antibodies are Associated with Low Levels of Complement C3 and C4 in Patients with Systemic Lupus Erythematosus. <i>Scandinavian Journal of Immunology</i> , <b>2016</b> , 84, 95-9	3.4	11

131	Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists. <i>Platelets</i> , <b>2020</b> , 31, 198-205	3.6	11
130	Effect of hormone replacement therapy on atherogenic lipid profile in postmenopausal women. <i>Thrombosis Research</i> , <b>2019</b> , 184, 1-7	8.2	10
129	Long-term outcome after pregnancy-related venous thrombosis. <i>Thrombosis Research</i> , <b>2015</b> , 135 Suppl 1, S1-4	8.2	10
128	Opposite circadian rhythms in melatonin and tissue factor pathway inhibitor type 1: does daylight affect coagulation?. <i>Journal of Thrombosis and Haemostasis</i> , <b>2006</b> , 4, 1840-2	15.4	10
127	Smoking and relation to other risk factors in postmenopausal women with coronary artery disease, with particular reference to whole blood viscosity and beta-cell function. <i>Journal of Internal Medicine</i> , <b>2003</b> , 253, 232-9	10.8	10
126	Polymorphisms of the coagulation system and risk of cancer. <i>Thrombosis Research</i> , <b>2016</b> , 140 Suppl 1, S49-54	8.2	10
125	Circadian rhythms of hemostatic factors in tetraplegia: a double-blind, randomized, placebo-controlled cross-over study of melatonin. <i>Spinal Cord</i> , <b>2015</b> , 53, 285-90	2.7	9
124	Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. <i>Platelets</i> , <b>2019</b> , 30, 206-212	3.6	9
123	Factor VII deficiency: Unveiling the cellular and molecular mechanisms underlying three model alterations of the enzyme catalytic domain. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2018</b> , 1864, 660-667	6.9	8
122	Outcome Assessment by Central Adjudicators Versus Site Investigators in Stroke Trials: A Systematic Review and Meta-Analysis. <i>Stroke</i> , <b>2019</b> , 50, 2187-2196	6.7	8
121	The chemical chaperone sodium 4-phenylbutyrate improves the secretion of the protein CA267T mutant in CHO-K1 cells through the GRASP55 pathway. <i>Cell and Bioscience</i> , <b>2015</b> , 5, 57	9.8	8
120	Protein C mutation (A267T) results in ER retention and unfolded protein response activation. <i>PLoS ONE</i> , <b>2011</b> , 6, e24009	3.7	8
119	Hereditary protein C deficiency caused by the Ala267Thr mutation in the protein C gene is associated with symptomatic and asymptomatic venous thrombosis. <i>Thrombosis Research</i> , <b>2010</b> , 125, 230-4	8.2	8
118	Functional characterization of the protein C A267T mutation: evidence for impaired secretion due to defective intracellular transport. <i>BMC Cell Biology</i> , <b>2010</b> , 11, 67		8
117	Extrinsic pathway inhibitor--the key to feedback control of blood coagulation initiated by tissue thromboplastin. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>1991</b> , 21, 219-39		8
116	Genome-wide analysis of genetic determinants of circulating factor VII-activating protease (FSAP) activity. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 16, 2024-2034	15.4	8
115	Genetic variations in the annexin A5 gene and the risk of pregnancy-related venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2015</b> , 13, 409-13	15.4	7
114	Immune activation and HIV-specific T cell responses are modulated by a cyclooxygenase-2 inhibitor in untreated HIV-infected individuals: An exploratory clinical trial. <i>PLoS ONE</i> , <b>2017</b> , 12, e0176527	3.7	7

113	Healthcare utilisation, induced labour and caesarean section in the pregnancy after stillbirth: a prospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2018</b> , 125, 202-210	3.7	7
112	Normalization of disrupted clock gene expression in males with tetraplegia: a crossover randomized placebo-controlled trial of melatonin supplementation. <i>Spinal Cord</i> , <b>2018</b> , 56, 1076-1083	2.7	7
111	Candidate gene polymorphisms and the risk for pregnancy-related venous thrombosis. <i>British Journal of Haematology</i> , <b>2012</b> , 157, 753-61	4.5	7
110	Long-term mortality and incidence of cancer after pregnancy-related venous thrombosis: results of a population-based cohort study. <i>Thrombosis Research</i> , <b>2013</b> , 131, 497-501	8.2	7
109	Tissue factor pathway inhibitor attenuates ER stress-induced inflammation in human M2-polarized macrophages. <i>Biochemical and Biophysical Research Communications</i> , <b>2017</b> , 491, 442-448	3.4	7
108	A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women. <i>Thrombosis Research</i> , <b>2012</b> , 130, 45-51	8.2	7
107	Symptom burden and job absenteeism after treatment with additional catheter-directed thrombolysis for deep vein thrombosis. <i>Patient Related Outcome Measures</i> , <b>2013</b> , 4, 55-9	2.9	7
106	Acute hypoxia and activation of coagulation. <i>Lancet, The</i> , <b>2003</b> , 362, 997-8	4.0	7
105	Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>1991</b> , 21, 254-7		7
104	Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. <i>Blood Coagulation and Fibrinolysis</i> , <b>1991</b> , 2, 425-33	1	7
103	Angiogenesis and hemostasis in hematological neoplasias. <i>Current Drug Targets</i> , <b>2005</b> , 6, 683-99	3	7
102	Determinants of acquired activated protein C resistance and D-dimer in breast cancer. <i>Thrombosis Research</i> , <b>2016</b> , 145, 78-83	8.2	7
101	The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2017</b> , 1, 49-56	5.1	6
100	Theme 4: Invasive management of (recurrent) VTE and PTS. <i>Thrombosis Research</i> , <b>2015</b> , 136 Suppl 1, S198-25		6
99	Indirect regulation of TFPI-2 expression by miR-494 in breast cancer cells. <i>Scientific Reports</i> , <b>2020</b> , 10, 4036	4.9	6
98	The role of inflammation in post-thrombotic syndrome after pregnancy-related deep vein thrombosis: A population-based, cross-sectional study. <i>Thrombosis Research</i> , <b>2016</b> , 138, 16-21	8.2	6
97	Reduced peak, but no diurnal variation, in thrombin generation upon melatonin supplementation in tetraplegia. A randomised, placebo-controlled study. <i>Thrombosis and Haemostasis</i> , <b>2015</b> , 114, 964-8	7	6
96	Reduced C4b-binding protein in preeclampsia. <i>Thrombosis Research</i> , <b>1997</b> , 85, 153-8	8.2	6

95	Validity and reliability of simple questions in assessing short- and long-term outcome in Norwegian stroke patients. <i>Cerebrovascular Diseases</i> , <b>2001</b> , 11, 305-10	3.2	6
94	Oral contraceptives highlight the genotype-specific association between serum phospholipids and activated factor VII. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1999</b> , 19, 2024-8	9.4	6
93	Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>1989</b> , 19, 189-95		6
92	The effect of the chemical chaperone 4-phenylbutyrate on secretion and activity of the p.Q160R missense variant of coagulation factor FVII. <i>Cell and Bioscience</i> , <b>2019</b> , 9, 69	9.8	5
91	Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 499-506	15.4	5
90	Functional characterization of annexin A5 gene promoter allelic variants. <i>Thrombosis Research</i> , <b>2016</b> , 144, 93-9	8.2	5
89	Does the Villalta scale capture the essence of postthrombotic syndrome? A qualitative study of patient experience and expert opinion. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1707-1714	15.4	5
88	The association of inherited thrombophilia and intrauterine fetal death: a case-control study. <i>Blood Coagulation and Fibrinolysis</i> , <b>2011</b> , 22, 651-6	1	5
87	Alterations in the extrinsic pathway in hypertriglyceridemia do not cause a 'procoagulant state': effects of bezafibrate therapy. <i>Blood Coagulation and Fibrinolysis</i> , <b>2001</b> , 12, 705-12	1	5
86	Air travel and risk of venous thromboembolism. <i>Thrombosis Research</i> , <b>2002</b> , 108, 15-7	8.2	5
85	TFPI fractions in plasma from patients with systemic meningococcal disease. <i>Thrombosis Research</i> , <b>2002</b> , 108, 347-53	8.2	5
84	Deep-vein thrombosis in long-haul flights. <i>Lancet, The</i> , <b>2001</b> , 358, 837-8; author reply 839	40	5
83	Indices of hypercoagulation in cancer as compared with those in acute inflammation and acute infarction. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , <b>1990</b> , 20, 253-62		5
82	Oestrogens Downregulate Tissue Factor Pathway Inhibitor through Oestrogen Response Elements in the 5'-Flanking Region. <i>PLoS ONE</i> , <b>2016</b> , 11, e0152114	3.7	5
81	Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer: Case reports and review of the literature. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 3189-3198	7.5	4
80	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. <i>Thrombosis Research</i> , <b>2018</b> , 163, 128-131	8.2	4
79	Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2016</b> , 36, 418-24	9.4	4
78	Immunobiology of heparin-induced thrombocytopenia. <i>Current Topics in Microbiology and Immunology</i> , <b>2010</b> , 341, 193-202	3.3	4

77	Interaction between tissue factor pathway inhibitor and factor V levels on the risk of venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 1130-2	15.4	4
76	Hypobaric hypoxia. <i>Lancet, The</i> , <b>2001</b> , 357, 955-956	4.0	4
75	Extrinsic pathway inhibitor in elective surgery: a comparison with other coagulation inhibitors. <i>Thrombosis and Haemostasis</i> , <b>1989</b> , 62, 856-60	7	4
74	Improved Functional Outcome After Additional Catheter-Directed Thrombolysis for Acute Iliofemoral Deep Vein Thrombosis: Results of a Randomized Controlled Clinical Trial (The CaVenT Study). <i>Blood</i> , <b>2011</b> , 118, LBA-1-LBA-1	2.2	4
73	Scalable production of tissue-like vascularised liver organoids from human PSCs		4
72	Outcome assessment by central adjudicators in randomised stroke trials: Simulation of differential and non-differential misclassification. <i>European Stroke Journal</i> , <b>2020</b> , 5, 174-183	5.6	4
71	Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists. <i>Platelets</i> , <b>2020</b> , 31, 322-328	3.6	4
70	Relationship between sex hormone binding globulin and blood coagulation in women on postmenopausal hormone treatment. <i>Blood Coagulation and Fibrinolysis</i> , <b>2019</b> , 30, 17-23	1	3
69	Activation of Endoplasmic Reticulum Stress and Unfolded Protein Response in Congenital Factor VII Deficiency. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 664-675	7	3
68	Limitations of the Villalta scale in diagnosing post-thrombotic syndrome. <i>Thrombosis Research</i> , <b>2019</b> , 184, 62-66	8.2	3
67	ETThromboglobulin may not reflect platelet activation during haemodialysis with the HeprAN membrane. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>2017</b> , 77, 679-684	2	3
66	Combined oral contraceptives increase risk of venous thrombosis according to oestrogen dose and type of progestogen. <i>Evidence-Based Medicine</i> , <b>2014</b> , 19, 194		3
65	Prophylaxis against prosthetic mitral valve thrombosis with unfractionated heparin administered by an elastometric infusion pump. <i>Thrombosis Research</i> , <b>2010</b> , 126, e232-4	8.2	3
64	Expression of the V264M TFPI mutant in endothelial cell cultures may involve mRNA stability. <i>Thrombosis Research</i> , <b>2009</b> , 123, 851-5	8.2	3
63	The viscosity of fibrinogen subfractions and of EDTA denatured fibrinogen do not differ from that of native fibrinogen. <i>Thrombosis Research</i> , <b>2004</b> , 113, 51-6	8.2	3
62	Reduction of factor FVIIa activity during heparin therapy. Evidence for assay interactions with tissue factor pathway inhibitor and antithrombin. <i>Thrombosis Research</i> , <b>2000</b> , 100, 389-96	8.2	3
61	Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , <b>1999</b> , 78, 191-197	3.8	3
60	Adjunctive Catheter-Directed Venous Thrombolysis in Iliofemoral Deep Vein Thrombosis; Short-Term Results from the CaVenT Study, a Multicenter Randomized Controlled Trial. <i>Blood</i> , <b>2008</b> , 112, 989-989	2.2	3

59	Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer. <i>Oncolmmunology</i> , <b>2020</b> , 9, 1824644	7.2	3
58	Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism. <i>Thrombosis Research</i> , <b>2020</b> , 196, 238-244	8.2	3
57	Utility of coagulation analyses to assess thromboprophylaxis with dalteparin in intensive care unit patients. <i>Acta Anaesthesiologica Scandinavica</i> , <b>2020</b> , 65, 489	1.9	3
56	Predictors of long-term post-thrombotic syndrome following high proximal deep vein thrombosis: a cross-sectional study. <i>Thrombosis Journal</i> , <b>2021</b> , 19, 3	5.6	3
55	Estrogen induced expression of tissue factor pathway inhibitor-2 in MCF7 cells involves lysine-specific demethylase 1. <i>Molecular and Cellular Endocrinology</i> , <b>2017</b> , 443, 80-88	4.4	2
54	Increased expression of TFPI in human carotid stenosis. <i>Thrombosis Research</i> , <b>2017</b> , 155, 31-37	8.2	2
53	Is venous thromboembolism a problem in patients with cancer in palliative care?. <i>Lancet Haematology,the</i> , <b>2019</b> , 6, e61-e62	14.6	2
52	Transcription factor FOXP3: A repressor of the TFPI gene?. <i>Journal of Cellular Biochemistry</i> , <b>2019</b> , 120, 12924-12936	4.7	2
51	Elevated Complement C3 and C4 Levels are Associated with Postnatal Pregnancy-Related Venous Thrombosis. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 1481-1488	7	2
50	Decreased lung cancer survival with hormone-replacement therapy: caused by a decreased tissue factor pathway inhibitor level?. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 2683-4; author reply 2684	2.2	2
49	Differences in circadian variations of tissue factor pathway inhibitor type 1 between able-bodied and spinal cord injured. <i>Thrombosis Research</i> , <b>2006</b> , 118, 281-7	8.2	2
48	Heparin Treatment of Recent Transient Ischemic Attacks: A Safety Study. <i>Cerebrovascular Diseases</i> , <b>1993</b> , 3, 174-176	3.2	2
47	Venous thrombosis with oral postmenopausal hormone therapy: Roles of activated protein C resistance and tissue factor pathway inhibitor. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 1729-1737	15.4	2
46	Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2495-2503	15.4	2
45	ARTS: A Large, International Trial of Thromboprophylaxis in Intra-abdominal, Gynecologic, and Urologic Surgery. <i>European Urology Focus</i> , <b>2021</b> , 7, 1222-1225	5.1	2
44	Evidence for long-term hypercoagulopathy, but normalization of markers of extracellular matrix turnover, in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 2479-81	1.9	1
43	Overexpression of tissue factor pathway inhibitor in CHO-K1 cells results in increased activation of NF- $\kappa$ B and apoptosis mediated by a caspase-3 independent pathway. <i>Molecular Biology Reports</i> , <b>2012</b> , 39, 10089-96	2.8	1
42	Genotype of proband and thrombophilia screening. <i>Blood</i> , <b>2013</b> , 122, 2528-9	2.2	1



41	Hormone replacement therapy and risk of venous thromboembolism--still unresolved questions. <i>Journal of Thrombosis and Haemostasis</i> , <b>2006</b> , 4, 68-9	15.4	1
40	Heparin versus aspirin in ischaemic stroke. <i>Lancet, The</i> , <b>2000</b> , 356, 505	40	1
39	Painting the Clinical Picture of Congenital Plasminogen Deficiency (C-PLGD) through a Comprehensive Case Study Review. <i>Blood</i> , <b>2020</b> , 136, 21-22	2.2	1
38	Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up.. <i>Journal of Thrombosis and Haemostasis</i> , <b>2022</b> ,	15.4	1
37	Evidence-based practice for patients with severe venous thrombosis. <i>Tidsskrift for Den Norske Laegeforening</i> , <b>2012</b> , 132, 1215-6	3.5	1
36	Production of Tissue Factor Pathway Inhibitor in Endothelial Cell Cultures Is Reduced by Estrogens, Selective Estrogen Receptor Modifiers, and a Selective Estrogen Receptor Downregulator.. <i>Blood</i> , <b>2005</b> , 106, 3961-3961	2.2	1
35	Extrinsic Coagulation Pathway Inhibitor during Recombinant Factor VIIa Infusion. <i>Thrombosis and Haemostasis</i> , <b>1989</b> , 62, 1146-1146	7	1
34	Severe syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP) in the 18th week of pregnancy associated with the antiphospholipid antibody syndrome <b>2003</b> , 82, 679		1
33	Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia. <i>Scientific Reports</i> , <b>2021</b> , 11, 5127	4.9	1
32	The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis. <i>Platelets</i> , <b>2020</b> , 31, 43-47	3.6	1
31	Effects of a 1-Year Physical Activity Intervention on Markers of Hemostasis among Breast Cancer Survivors: A Randomized Controlled Trial. <i>TH Open</i> , <b>2021</b> , 5, e14-e23	2.7	1
30	Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> ,	15.4	1
29	Tissue factor pathway inhibitor: clinical deficiency states. <i>Thrombosis and Haemostasis</i> , <b>1997</b> , 78, 467-70	7	1
28	The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis. <i>Thrombosis Research</i> , <b>2019</b> , 177, 154-156	8.2	0
27	Hormone therapy and raloxifene reduce the coagulation inhibitor potential. <i>Blood Coagulation and Fibrinolysis</i> , <b>2007</b> , 18, 455-60	1	0
26	Heparin and aspirin in stroke. <i>Lancet, The</i> , <b>2001</b> , 357, 1044-5	40	0
25	Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4551-4551	2.2	0
24	Tissue factor pathway inhibitor and bleeding tendency: can hormonal state explain the differences?. <i>Blood Advances</i> , <b>2021</b> , 5, 2516-2517	7.8	0

23	Prevention of post-thrombotic syndrome with rosuvastatin: A multicenter randomized controlled pilot trial (SAVER).. <i>Thrombosis Research</i> , <b>2022</b> , 213, 119-124	8.2	o
22	Reply: Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in the management of major bleeding: Methodological issues. <i>Journal of Thrombosis and Haemostasis</i> , <b>2019</b> , 17, 1398-1399	15.4	
21	Antiplatelet Therapy in Noncardioembolic Stroke: A Review of Current Evidence. <i>Seminars in Neurology</i> , <b>2017</b> , 37, 366-375	3.2	
20	Catheter-directed thrombolysis for acute deep vein thrombosis [Authors' reply]. <i>Lancet, The</i> , <b>2012</b> , 379, 1786-1787	4.0	
19	C0298 Differential risk factors for pregnancy related deep vein thrombosis and pulmonary embolism' results from a population-based case-control study. <i>Thrombosis Research</i> , <b>2012</b> , 130, S122-S123	8.2	
18	Associations between regulators of extracellular matrix and hemostatic factors in hematologic neoplasias. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 1157-9	1.9	
17	Tissue factor pathway inhibitor revisited. <i>Journal of Thrombosis and Haemostasis</i> , <b>2004</b> , 2, 2242-2243	15.4	
16	PREACTIVATION AND INHIBITION OF EXTRINSIC COAGULATION PATHWAY IN ACUTE CORONARY DISEASE <b>1987</b> , 58, 0225		
15	NEW COAGULATION INHIBITORS LEVELS IN PNEUMONIA DISSEMINATED INTRAVASCULAR COAGULATION AND LIVER DISEASES <b>1987</b> , 58, 1115		
14	EXTRINSIC PATHWAY INHIBITOR (EPI):A SENSITIVE CHROMOGENIC SUBSTRATE ASSAY DEMONSTRATES THE RELEASE OF EPI TO THE BLOOD AFTER INJECTION OF HEPARIN <b>1987</b> , 58, 1116		
13	EXTRINSIC PATHWAY INHIBITOR (EPI) DURING ELECTUVE SUGERY : A COMPARISON WITH OTHER COAGULATION INHIBITORS <b>1987</b> , 58, 1526		
12	Characterizing Coagulation FVII from iPSC-Hepatocytes-like Cells: Setting the Basis for Cell Therapy Development. <i>Blood</i> , <b>2020</b> , 136, 4-4	2.2	
11	Successful Pregnancy in a Patient with Infertility Due to Congenital Plasminogen Deficiency Treated with Intravenous Plasminogen (Human) Replacement Therapy. <i>Blood</i> , <b>2020</b> , 136, 5-6	2.2	
10	Molecular Characterization of Two Homozygous Factor VII Variants Associated with Intracranial Bleeding. <i>Blood</i> , <b>2020</b> , 136, 21-22	2.2	
9	Low Dose Apixaban As Secondary Prophylaxis for Venous Thromboembolism in Cancer Patients, 30 Months Follow-up. <i>Blood</i> , <b>2021</b> , 138, 3231-3231	2.2	
8	Pivotal Trial with Intravenous Plasminogen Replacement in Patients with Plasminogen Deficiency Demonstrates Long-Term Efficacy for Treatment and Prevention of Ligneous Lesions. <i>Blood</i> , <b>2017</b> , 130, 84-84	2.2	
7	Tissue Factor Pathway Inhibitor Enhances Transendothelial Migration of Chronic Lymphocytic Leukemia Cells through Binding to Glypican-3. <i>Blood</i> , <b>2018</b> , 132, 2452-2452	2.2	
6	Thrombin-Generating Capacity of Microvesicles (MVs) in Patients with Immune Thrombocytopenia (ITP) before and during Treatment with Thrombopoietin-Receptor Agonists (TPO-RA). <i>Blood</i> , <b>2018</b> , 132, 2511-2511	2.2	

- 5 The Chemical Chaperone 4-Phenylbutyrate Increases Secretion and Activity of Missense and Elongated Factor VII Mutants. *Blood*, **2018**, 132, 3777-3777 2.2
- 4 Increased Bone Marrow Microvascular Density in Hematologic Malignancies. *Blood*, **2008**, 112, 5456-5456.2
- 3 Candidate Gene Polymorphisms and the Risk for Pregnancy Related Venous Thrombosis. *Blood*, **2010**, 116, 4203-4203 2.2
- 2 The Factor VII Variant p.A354V-p.P464Hfs: Clinical versus Intracellular and Biochemical Phenotypes Induced by Chemical Chaperones. *Applied Sciences (Switzerland)*, **2021**, 11, 5762 2.6
- 1 Prior Thromboembolic Disease and Assisted Reproductive Therapy. *Seminars in Reproductive Medicine*, **2021**, 39, 180-185 1.4